Clinical trial: Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19) (NCT04565392)

Eligibility criteria:
Inclusion Criteria:

          1. - Probable COVID-19 based on presence of at least 5 of the following symptoms of acute
             onset within the prior 4 days: fever, cough, sore throat, fatigue, episodic chest pain
             or shortness of breath with exercise, muscle or body aches, headache, loss of smell or
             taste, stuffy or runny nose, chills or shivering, feeling hot or feverish, nausea,
             diarrhea

          2. - Subjects must signify that they have contacted a doctor about their current
             symptoms.

          3. - Subject gives informed consent for study and is willing to take the treatments and
             complete the scheduled evaluations.

          4. - Subject has acquired a study partner who has agreed to complete the follow-up forms
             for the subject if the subject unable or has been hospitalized.

        Exclusion Criteria:

          1. - Constant rather than episodic trouble breathing, Persistent pain or pressure in the
             chest, New confusion, Inability to wake or stay awake, Bluish lips or face, or any
             other severe symptom [symptoms CDC urges immediate medical care for].

          2. - Known sensitivity or intolerance to famotidine or another acid-blocking drug.

          3. - Lack of access to the internet at home.

          4. - Using tizanidine (Zanaflex® , a muscle relaxant), dasatinib (Sprycel®, a drug for
             leukemia), cefditoren (Pivoxil®, an antibiotic), or fosamprenavir or delavirdine
             (drugs for HIV) [Drug exclusions are per US label for Pepcid].

          5. - Significant heart or kidney disease in the last 3 months according to subject's
             primary doctor

          6. - Pregnant women

          7. - Taking any investigational medications to treat COVID-19, famotidine, anti-viral
             drugs or corticosteroids and not stopping them within 48 hours before starting study
             treatment.

        NOTE: patients are allowed to take over-the-counter agents for temporary relief of symptoms
        such as antipyretics and analgesics (aspirin, ibuprofen etc), cough remedies,
        anti-diarrheals, etc.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Patient description (medical language): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient description (patient's own words): I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Does the patient match the trial criteria? Entailment